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MOLECULAR CARCINOGENESIS
The Proto-Oncogene PBF Binds p53 and Is Associated
With Prognostic Features in Colorectal Cancer
Martin L. Read,1 Robert I. Seed,1 Bhavika Modasia,1 Perkin P.K. Kwan,1 Neil Sharma,1 Vicki E. Smith,1
Rachel J. Watkins,1 Sukhchain Bansal,1 Teresa Gagliano,2 Anna L. Stratford,3 Tariq Ismail,4
Michael J.O. Wakelam,5 Dae S. Kim,1 Stephen T. Ward,6 Kristien Boelaert,1 Jayne A. Franklyn,1
Andrew S. Turnell,4 and Christopher J. McCabe1*
1School of Clinical and Experimental Medicine, University of Birmingham, UK
2University of Ferrara, Ferrara, Italy
3Department of Pediatrics, University of British Columbia, Canada
4School of Cancer Sciences, University of Birmingham, UK
5The Babraham Institute, Babraham Research Campus, UK
6Centre for Liver Research and NIHR Centre for Biomedical Research Unit, University of Birmingham, UK
The PTTG1-binding factor (PBF) is a transforming gene capable of eliciting tumor formation in xenograft models.
However, the precise role of PBF in tumorigenesis and its prognostic value as a cancer biomarker remain largely
uncharacterised, particularly in malignancies outside the thyroid. Here, we provide the first evidence that PBF represents a
promising prognostic marker in colorectal cancer. Examination of a total of 39 patients demonstrated higher PBF
expression at both themRNA (P¼ 0.009) and protein (P< 0.0001) level in colorectal tumors compared tomatched normal
tissue. Critically, PBF was most abundant in colorectal tumors associated with Extramural Vascular Invasion (EMVI),
increased genetic instability (GI) and somatic TP53 mutations, all features linked with recurrence and poorer patient
survival. We further demonstrate by glutathione–S–transferase (GST) pull-down and coimmunoprecipitation that PBF
binds to the tumor suppressor protein p53, as well as to p53 mutants (D126–132, M133K, V197E, G245D, I255F and
R273C) identified in the colorectal tumors. Importantly, overexpression of PBF in colorectal HCT116 cells interfered with
the transcriptional activity of p53-responsive genes such as mdm2, p21 and sfn. Diminished p53 stability (> 90%;
P< 0.01) was also evident with a concurrent increase in ubiquitinated p53. Human colorectal tumors with wild-type TP53
and high PBF expression also had low p53 protein levels (P<0.05), further emphasizing a putative interaction between
these genes in vivo. Overall, these results demonstrate an emerging role for PBF in colorectal tumorigenesis through
regulating p53 activity, with implications for PBF as a prognostic indicator for invasive tumors.
© 2014 The Authors. Molecular Carcinogenesis published by Wiley Periodicals, Inc.
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INTRODUCTION
Colorectal cancer is the second leading cause of
cancer-related deaths in developed countries [1]. Ten-
year survival rates for patients with colorectal cancer
have increased to 50% in the past 30 yr. However, a
better understanding of the underlying molecular
mechanisms will be needed to identify suitable
therapeutic targets to improve long-term survival.
Genetic alterations that initiate and promote colorec-
tal tumorigenesis have been well-defined and include
mutations in the adenomatous polyposis coli (APC)
gene, the b-catenin gene CTNNB1 and BRAF [2,3]. The
precise role of proteins that have been proposed to
affect later stages of colorectal tumorigenesis such as
p53, Smad4, DCC and K-Ras [4] still need further
investigation to facilitate their usefulness as potential
therapeutic targets.
Among these, inactivation of the tumor suppressor
protein p53 has been identified as a critical event in
the pathogenesis of most cancers, with well-estab-
lished roles in cell-cycle regulation, apoptosis and
senescence [5]. New roles for p53 in intestinal
tumorigenesis have recently been identified in mu-
rine models, including those involved in invasiveness
control [6,7], creation of an inflammatory microenvi-
ronment [8] and the induction of epithelial-
mesenchymal transition (EMT) [8]. In addition, it
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has emerged that p53-regulated transcription of
miRNAs such as the miR-34 family may be involved
in controlling migration [9], invasion [9] and
EMT induction [10,11] of colorectal cancer cells.
These studies emphasize the importance of identify-
ing how p53 activity is modulated in colorectal
cancer to help define the pathways integral to
tumorigenesis.
Typically p53 inactivation is considered a late event
involved in the transition of benign tumors to
invasive colorectal cancer [4,12]. It has been well-
characterised that inactivating mutations of the TP53
gene can occur in up to 50% of colorectal tumors, and
their frequency increases with advancing tumor
stage [13]. In contrast, far less is known about how
p53 activity is regulated by oncogenes that are
commonly overexpressed in colorectal cancer. A
well-described example is the human securin pitui-
tary tumor-transforming gene 1 (PTTG1) which is a
marker for invasive colorectal carcinoma [14] and was
identified as a key signature gene associated with
tumor metastasis [15]. The functional interaction
between PTTG1 and p53 has been demonstrated in
transformed cells [16,17]. However, it is unclear
whether proteins that physically interact with
PTTG1, such as the PTTG1-binding factor (PBF) [18],
Ku70 [19], ribosomal protein S10 [20] and DNAJA1
[20], can modulate the effects of PTTG1 on p53
activity.
Also known as PTTG1-interacting protein
(PTTG1IP), PBF was first identified through its ability
to bind and facilitate nuclear translocation of PTTG1
[18]. In subsequent studies we have described PBF
overexpression in thyroid [21], pituitary [22] and
breast cancers [23]. Functional studies highlighted
that PBF was a transforming gene in vitro and
induced subcutaneous high-grade malignant tumor
formation in athymic nude mice [21]. PBF over-
expression in breast MCF-7 cells led to increased cell
invasion, which could be abrogated both by small
interfering RNA (siRNA) treatment and specific
mutation [23]. We further demonstrated that thy-
roid-targeted expression of PBF in transgenic mice
resulted in the induction of hyperplastic growth
and macrofollicular thyroid lesions [24]. Collective-
ly, these observations indicated that PBF has
particular relevance to endocrine and breast tumor-
igenesis, but its precise role in neoplasia was not
established.
In this study we show for the first time that PBF
is overexpressed in the non-endocrine setting of
human colorectal tumors, and particularly in invasive
tumors. Furthermore, we present evidence suggesting
that PBF binds and acts as a novel regulator of p53 in
colorectal cancers, an action that appears to be
independent of PTTG1. This study therefore identifies
a new pathway of p53 inactivation in tumorigenesis,
and thus provides insights into understanding the
pathogenesis of colorectal cancer.
MATERIALS AND METHODS
Human Tissue Samples
Matched tumor and normal tissue specimens were
obtained from 39 patients undergoing surgery for
colorectal cancer at the University Hospital Birming-
ham NHS Trust, UK. Upon gross clinical inspection
normal samples of non-tumorous appearance were
taken with a fresh scalpel blade at least 10 cm from
the tumor (proximal or distal depending on the
resection). Tumor tissue was then sampled using
a fresh scalpel blade to limit contamination of
colorectal samples. All specimens harvested at the
time of resection were collected with appropriate
local ethical committee approval and informed
patient consent.
Cell Culture
Human colorectal cancer HCT116 cells were
obtained from the Health Protection Agency Culture
Collections, UK and routinely cultured in McCoy’s
5 A (Life Technologies) supplemented with 10% fetal
bovine serum (Invitrogen), penicillin (105 U/L) and
streptomycin (100 mg/L) [Invitrogen]. H1299 and
MCF-7 cells were routinely cultured in RPMI 1640
(Life Technologies) supplemented with 10% fetal
bovine serum (Invitrogen), penicillin (105 U/L) and
streptomycin (100 mg/L). All cell lines were kept at
low passage number. HCT116 [25] and MCF-7 cells
express WT p53, whereas H1299 cells are p53-null.
Nucleic Acids and Transfections
The QuikChange II XL site-directed mutagenesis kit
(Agilent Technologies) was used to delete amino acids
149–180 (M1) and 94–149 (M2) of PBF, as well as to
generate six p53 mutants [D126–132 (M1), M133 K
(M2), V197E (M3), G245D (M4), I255F (M5) and
R273C (M6)]. WT p53 and mutants were cloned into
pcDNA3 for mammalian cell expression experiments.
WT PBF, M1 and M2 were cloned into pGEX4T-1 for
bacterial expression. The PBF and mutant vectors for
expression in mammalian cells [26], the p53 reporter
plasmid phdm2-Luc [27] and the haemagluttin (HA)-
tagged ubiquitin (Ubq-HA) construct [28] have been
described previously.
Small interfering RNA (siRNA) and plasmid DNA
transfections were performed with Lipofectamine-
2000 (Invitrogen), Fugene (Roche) and TransIT LT1
(Mirus Bio LLC) according to manufacturer’s proto-
col. Cells were transfected using pooled PBF-specific
siRNA (catalog nos. 4399 and 147 350) or negative
control siRNA (AM4635) at a final concentration of
100 nM (Ambion). In transient reporter assays
H1299 cells were transfected with PBF expression
vectors (400 ng), pcDNA3-p53 (5 ng), pRL (20 ng)
and phdm2-Luc (150 ng). After 24 h cells were
harvested in Passive Lysis Buffer and luciferase
activity measured using the Dual Luciferase Reporter
Assay System (Promega).
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Western Blotting
Western blot analyses were performed as described
previously [23,26]. Blots were probed with specific
antibodies against PBF [23,26], 1:500; HA (Covance
Research Products), 1:2000 and p53(D0–1) (Santa
Cruz Biotechnology), 1:1000. Antigen-antibody com-
plexes were detected using the ECL Plus chemilumi-
nescent detection system (Amersham Biosciences).
Actin expression was determined using mouse mono-
clonal anti-b actin antibody clone AC-15 (Sigma-
Aldrich) at 1:10,000. Protein quantification was
performed on cell lysates using the Bradford assay.
To quantify detected bands by densitometry, blots
were scanned into Photoshop (Adobe Systems)
keeping all scanning parameters the same and
analysed using ImageJ software [29].
Real-Time RT-PCR and Sequencing
Total RNA was extracted using the RNeasy Micro Kit
(Qiagen) and reverse transcribed using the Reverse
Transcription System (Promega). Expression of spe-
cific mRNAs was determined using 7500 Real-time
PCR system (Applied Biosystems) as previously
described [24]. Colorectal tumor cDNA was sequenced
to determine p53 mutational status as described with
minor modifications [30]. Details of sequencing
primers are given in Supplementary Figure S1A.
p53 Binding and Stability Assays
L-a-[35S]-methionine-labelled p53 was expressed
in vitro using a TNT T7 Coupled Reticulocyte Lysate
System according to the manufacturer’s guidelines
(Promega). In vitro glutathione-S-transferase (GST)
pull-down assays using [35S]-p53 and GST-PBF pro-
teins were performed using established protocols [31].
Coimmunoprecipitation (co-IP) assays were per-
formed as described previously [26]. In p53 half-life
experiments cells were incubated in 100 mM aniso-
mycin for 2 h prior to cell lysate extraction using
standard protocols. In p53 ubiquitination experi-
ments cells were incubated in 20 mM MG132 for 5 h
prior to cell lysate extraction.
Biotinylated Oligonucleotide Pull-down Assay
Oligonucleotide pull-downs were performed essen-
tially as described previously [32]. An oligonucleotide
(p21, Supplementary Figure S2A) containing a con-
sensus p53 binding sequence was 5’end labelled with
biotin and incubated with 25 ng recombinant human
p53 protein (Active Motif, #31318). The DNA binding
mixture contained 2.5 nM biotinylated DNA,
200 mM NaCl, 3 mM DTT, 25 mM HEPES-OH (pH
7.5), 0.2 mM EDTA, 0.1% Tween-20, 5% glycerol and
1 mg poly(dA-dT). In competition reactions non-
biotinylated oligonucleotide, recombinant PBF pro-
tein or BSA was also added to the binding reaction as
indicated. DNA/protein complexes were captured
with 5 mg of magnetic streptavidin beads (Promega).
Subsequently, bound proteins were probed with an
anti-p53 antibody (Santa Cruz Biotechnology). Prior
to use magnetic beads were incubated in 7 mg/ml
acetylated BSA for 30 min to prevent non-specific
binding of p53. Oligonucleotide sequences are given
in Supplementary Figure S2A.
Proximity Ligation Assay
The Duolink in situ proximity ligation assay (PLA)
was performed according to the manufacturer’s
instructions (Olink Bioscience). In our experiments
MCF-7 cells were seeded onto coverslips and trans-
fected with expression vectors for p53 (pcDNA3-p53)
and HA-tagged PBF (pcDNA3-PBF-HA) for 24 h prior
to performing the PLA assay.
Soft Agar Assays, Irradiation and Cell Viability
Stable transfections in NIH3T3 cells and subsequent
soft agar assays were performed as described previ-
ously [21]. DNA damage was induced by Caesium 137
irradiation using an irradiator IBL 437 C type H unit
(CIS Bio international, Gif Sur Yvette). The cellular
viability of HCT116 cultures transfected with either
VO or PBF was determined using the MTT assay as
described previously [33].
Immunohistochemistry and Genetic Instability
Formalin-fixed paraffin embedded sections of
colorectal tissue were immunostained using an
avidin-biotin peroxidase technique (Vectastain Elite,
Vector laboratories, Burlingame, CA). Immuno-
staining was performed with specific antibodies
against PBF [23,26], 1:200 as described previously [21].
FISSR-PCR to assess genetic instability (GI) of colorec-
tal tumors was performed using primer (CA)8RG as
described previously [34].
Cell Migration
HCT116 cell migration experiments were per-
formed using the ORISTM Cell Migration Assay
(Platypus Technologies) according to the manufac-
turer’s protocols. Briefly, the cell stopper was removed
after seeding 50,000 HCT116 cells per 96 well for 16 h.
Cells were then washed gently with 100 ml sterile PBS,
fed with 100 ml culture media and incubated for 24 h
at 37 8C with 5% CO2 prior to analysis of cell
migration. At least eight wells were analysed per
condition which involved imaging cells with an
inverted light microscope and digital camera (Leica
Microsystems). ImageJ software was used to process
the image and quantify the proportion of migrating
cells.
Statistical Analysis
Data are displayed as mean SE. Normally distrib-
uted data were analysed using a two-tailed Student’s t-
test, unless otherwise indicated. A P-value<0.05 was
considered to be statistically significant.
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RESULTS
Overexpression of PBF in Human Colorectal Tumors
Based on our previous findings that PBF expression
was upregulated in thyroid cancer [21], we investigat-
ed whether PBF was also overexpressed in colorectal
cancer and might therefore represent a prognostic
indicator. Tumors showed 2.4-fold higher PBF mRNA
expression than matched normals (Figure 1A; n¼24;
P¼0.009). Immunohistochemistry revealed signifi-
cant positive granular staining for PBF in the cyto-
plasm of adenocarcinomas, with weak or absent PBF
staining in normal tissue specimens (Figure 1B).
Protein expression was quantified through Western
blotting in a further 15 matched normal [N] and
cancer [C] colorectal specimens. 14/15 (93.3%) of
tumors demonstrated significant PBF upregulation
(Figure 1C), with a mean6-fold induction of protein
compared to matched normal tissue (Figure 1D;
P<0.0001). Altogether these results demonstrate
that PBF expression is elevated in colorectal tumors
and thus represents a potential prognostic marker.
PBF Promotes Colony Formation Independent of PTTG1-
Binding Domain
To investigate whether the interaction between PBF
and the human securin PTTG1 might have a role in
tumorigenesis [18], we evaluated the transformation
ability of PBF and a mutant of PBF (M1) lacking the
entire PTTG1-binding domain (PTTG1 BD). Consis-
tent with previous data [21], stable overexpression
of PBF in NIH-3T3 cells resulted in the formation
of highly significant numbers of colonies in soft
agar assays compared to VO cells (Supplementary
Figure S3; VO 9.11.4 colonies; PBF 20133.2;
P<0.001). However, mutant PBF (M1) was still
capable of transforming NIH-3T3 cells with a signifi-
cant number of colonies (Supplementary Figure S3;
M1 17523.5; P<0.001), thus implying that the
transforming ability of PBF is not dependent on
PTTG1.
PBF Binds to p53
We next examined whether PBF interacts with
p53, a protein critical in suppressing human
cancers. Initial GST pull-down assays demonstrated
that L-a-[35S]-methionine-labeled p53 binds to the
full-length PBF protein but not with the GST control
(WT 1–180; Figure 2A). Deletion mutants of GST-PBF
altered the stringency of p53 binding. For instance, a
mutant of PBF lacking amino acids 149–180 (M1)
retained p53 binding, whereas the p53 interaction
was lost with a mutant lacking amino acids 94–149
(M2). We next investigated whether the two proteins
were able to bind in colorectal cancer HCT116 cells.
Following irradiation of cells PBF was precipitated
with an anti-PBF antibody. Coimmunoprecipitation
of p53 with PBF was observed by probing with an anti-
p53 antibody following Western blotting (Figure 2B)
with a two-fold greater level of intensity than in non-
irradiated HCT116 cells (Figure 2C; P<0.01; n¼3).
Analysis of total protein cell lysate confirmed in-
creased p53 expression in irradiated cells whereas PBF
protein level was unaltered compared to controls
(Figure 2B).
The reciprocal co-immunoprecipitation was per-
formed using the anti-p53 antibody for precipitation
of p53 and immunoblotting for PBF, which resulted in
Figure 1. Elevated PBF expression in colorectal tumors. (A) PBF mRNA levels in matched normal and tumor
colorectal pairs (n¼ 24). Data presented as mean SE. (B) Representative images of PBF immunostaining in
matched normal (i, iii) and colorectal tumor specimens (ii, iv). (C)Western blot analysis of PBF expression inmatched
normal [N] and cancer [C] colorectal pairs along with a b-actin loading control (n¼ 15). (D) Quantification of PBF
protein expression in colorectal tumors relative to normal tissue (n¼ 15). Data presented as a scatterplot and
analysed using Wilcoxon signed-rank test. **P< 0.01; ***P < 0.001.
4 READ ET AL.
Molecular Carcinogenesis
successful co-immunoprecipitation (Figure 2D). In
subsequent experiments we examined the binding
interaction after exogenous expression of p53 and PBF
(Figure 2E). Following the transient transfection of
PBF and p53 into HCT116 cells PBF was precipitated
with an anti-PBF antibody. The greatest amount of
p53 co-immunoprecipitated with PBF was evident
in HCT116 cells transfected with both p53 and PBF
but was not present in the no-antibody control
(Figure 2E).
The ability of PBF to interact with p53 was further
examined using an oligonucleotide pull-down assay
based on a p21 consensus binding site [32]. Binding of
recombinant p53 was successively diminished by
incubation with increasing amounts of recombinant
PBF, but was unaltered by competition with excess
BSA (Figure 2F, top panel). Furthermore, competition
hinged upon the ability of PBF to bind p53, as PBF
mutant M1 retained the ability to compete for p53
binding, whereas there was no significant reduction
in p53 binding with PBF mutant M2 protein
(Figure 2F, lower panel). In control experiments the
specificity of p53 binding was demonstrated by a lack
of competition with oligonucleotides containing
either a mutated p53 sequence (MUT) or a non-
related sequence (CON) (Supplementary Figure S2B).
In parallel experiments proximity ligation assays also
demonstrated the presence of red spots of specific p53
and PBF interaction in MCF7 cells after transient
(Supplementary Figure S2C). Altogether these results
demonstrate that PBF protein binds to p53 both
in vitro and in the cellular environment in colorectal
cells.
PBF Increases Turnover and Ubiquitination of p53
p53 is an intrinsically unstable protein which is
subject to degradation both in the nucleus and
cytoplasm. We next examined whether the interac-
tion of PBF with p53 resulted in altered protein
stability. Half-life studies using anisomycin to block
de novo protein synthesis showed that overexpres-
sion of PBF resulted in significantly increased turn-
over of p53 protein in HCT116 cells, with a 90%
decrease in p53 levels compared to VO controls after
120 min (Figure 3A and B; P<0.01; n¼4). Further
evidence of diminished p53 stability in PBF-trans-
fected HCT116 cells was shown by an increased level
of high mwt p53 conjugates in the presence of the
proteasome inhibitor MG132 (Figure 3C), and in cells
cotransfected with HA-tagged ubiquitin (Ubq-HA)
and p53 (Figure 3D), which are consistent with the
accumulation of ubiquitinated p53. Analysis of p53
Figure 2. PBF binds p53 in vitro. (A) Binding of [35S]-p53 to GST-
PBF (1–180) and GST-PBF deletion mutants M1 and M2 as indicated
versus a GST-only control. (B) Coimmunoprecipitation (co-IP) assay
in untreated (  ) or irradiated (þ) HCT116 cells showing interaction
between PBF and p53. Cell lysates were immunoprecipitated
with an anti-PBF antibody. Purified proteins were analysed by
Western blotting using an anti-p53 antibody. (lower) Analysis of
total protein lysate demonstrating the presence of p53 and PBF
along with a b-actin control. (C) Quantification of mean p53 protein
levels SE from 3 independent co-IP assays described in (B). **,
P< 0.01. (D) Reciprocal co-IP assay in untreated HCT116 cells
showing interaction between PBF and p53. Asterisk indicates
position of 30 kDa band corresponding to PBF. (lower) Immuno-
precipitation of PBF in total protein lysates. (E) Co-IP assays in
HCT116 cells transfected with PBF p53, or PBF and p53. Co-IP assays
were performed as described in (B). (lower) Western blotting analysis
to confirm exogenous expression of p53 and PBF along with b-actin
control. (F) Oligonucleotide pull-down analysis of p53 binding to a
consensus p21 promoter in the presence of increasing amounts of
recombinant PBF compared to BSA (upper), a control (CON)
oligonucleotide (upper), or recombinant PBF mutant proteins M1
and M2 as indicated (lower). Values indicate fold (x) molar excess
relative to p53. NAb¼ no antibody control.
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mRNA levels also revealed no change in PBF-trans-
fected HCT116 cells (Figure 3E), which indicated that
the effects of PBF on p53 were primarily at the level of
protein stability and not transcriptional.
PBF Modulates p53 Activity
Given that PBF binds p53, we next analyzed the
effect of PBF on the transactivation activity of p53 in
transient reporter assays using p53-null H1299 cells.
When coexpressed with p53, PBF significantly
repressed p53-mediated hdm2 promoter activity by
up to 50% (Figure 4A; P<0.0001) in H1299 cells.
PBF mutant M1, which retained p53 binding in the
GST pull-down assay, also repressed p53-mediated
hdm2 promoter activity (Figure 4B; P<0.0001), but
the PBF mutant M2, which did not bind p53, was
unable to repress p53 transcriptional activity
(P¼NS).
In normal cells p53 is maintained at low levels but
stabilized by irradiation-induced DNA damage. We
therefore first determined the optimal p53 response in
irradiated HCT116 cells (Figure 4C) and then exam-
ined the influence of manipulating PBF expression on
cell survival in response to irradiation. In the absence
of PBF, HCT116 cell survival was reduced by 30%
following exposure to irradiation (Figure 4D). In
contrast, cells transfected with PBF demonstrated no
decrease in cell survival, and indeed showed signifi-
cantly greater cell number than irradiated VO-trans-
fected cells (P<0.01). Examination of p53 regulated
genes indicated that PBF overexpression had ablated
the ability of irradiation to induce mRNA levels for
genes such as p21 (Figure 4E; P<0.05), mdm2
(Figure 4E; P < 0.05), bax (Supplementary Figure S4;
P<0.05) and sfn (Supplementary Figure S4; P<0.05)
compared to irradiated VO-transfected cells. To
determine whether the reverse relationship held
true, we depleted PBF (Figure 4F) and observed
significant increase in p53 activity in HCT116 cells
with elevated p21 (Figure 4F; P<0.001) and sfn
(Supplementary Figure S5; P<0.05) mRNA levels.
Together these results provide compelling evidence
for the functional ability of PBF to modulate p53
activity in colorectal cells.
PBF Expression Correlates with p53 Status
Colorectal cancers are known to contain a high
frequency of TP53 mutations that alter stability of
the p53 protein as well as cellular function [35,36].
To gain further insight into the association between
p53 and PBF in vivo we next compared the
mutational status and relative expression of p53 in
a cohort of 15 matched human normal (N) and
cancer (C) colorectal specimens against their PBF
expression levels as described in Figure 1C. Screen-
ing of our 15 matched colorectal specimens identi-
fied 8 tumors that contained either a nonfunctional
somatic TP53 mutation or deletion (Figure 5A and
Supplementary Figure S1B). Highly stabilized p53
protein was also evident in these mutant p53
colorectal tumors (n¼8) with a mean 20.63.8-
fold higher relative level of p53 expression than in
WT p53 tumors (P<0.001; n¼7; Figure 5B). Further
details of the TP53 mutations identified in these
Figure 3. PBF regulates p53 stability. (A) Western Blot analysis of
p53 and PBF in HCT116 cells transfected with either VO or PBF and
then lysed at indicated times post-treatment with 100mManisomycin.
Exogenous PBF was detected with an anti-HA antibody. (B)
Quantification of mean p53 protein levels relative to b-actin from 4
independent experiments as described in (A). (C) Detection of high
molecular weight p53 conjugates by Western blot analysis in HCT116
cells transfected with either VO or PBF and then treated with 10mM
MG132. (D) Detection of high molecular weight HA-tagged ubiquitin
(Ubq-HA) conjugates by Western blot analysis in HCT116 cells
transfected with either VO or PBF, as well as p53 and Ubq-HA as
indicated, and then treated with MG132. (E) Relative p53 mRNA levels
in HCT116 cells transfected with either VO or PBF. Data presented as
mean SE. *, P< 0.05; **, P< 0.01; ***, P< 0.001. NS - not
significant.
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colorectal tumors and associated clinical data are
given in Supplementary Tables S1 and S2.
To improve detection of the lower expression of
p53 in WT TP53 tumors we quantified immunoblots
at higher exposure as shown in Supplementary
Figure S6. An inverse relationship was apparent
between p53 and PBF such that colorectal tumors
with WT TP53 and high PBF expression (>2-fold
induction) had reduced p53 protein levels compared
to those with low PBF expression (Figure 5C;
P<0.05). In addition, all tumors with mutated
TP53 were associated with higher PBF expression
compared to those with WT TP53 (Figure 5D; P <
0.05). Having observed strong evidence for PBF
binding to WT p53, we next examined whether PBF
was also able to bind to mutant p53. Following
transient transfection of PBF and six of the p53
mutants (M1-M6) identified in the human colorectal
tumors (Figure 5B), PBF was precipitated with an
anti-PBF antibody. Coprecipitation for all 6 p53
mutants studied with PBF was observed following
Western blotting using an anti-p53 antibody at up to
5.7-fold greater intensity than WT p53 (Figure 5E).
In contrast, p53 was not detected in controls in
which PBF and empty vector (  ) were transfected.
Analysis of total protein cell lysate demonstrated the
presence of exogenous PBF and mutant p53 protein
(Figure 5E).
These results provide evidence for a signification
correlation between PBF and p53 expression levels
in vivo, as well as the impact of mutant p53 status on
these associations.
Figure 4. Altered expression of p53-regulated genes by PBF. (A)
Fold induction of luciferase reporter activity in H1299 cells seeded at
either 20 or 50 103 per well and transfected with p53 and PBF
expression vectors as indicated. (B) Fold induction of luciferase reporter
activity in H1299 cells transfected with p53, PBF and PBF mutant (M1
orM2) expression vectors as indicated. (C)Western blot analysis of p53
in HCT116 cells irradiated with 0- to 40-Gy dose as indicated for 8 h
(upper), or irradiated with 15-Gy dose and p53 protein levels
monitored at 0, 2, 8, or 24 h after treatment compared with untreated
(  ) controls (lower). (D) Cell viability of HCT116 cells transfected with
either VO or PBF for 24 h and irradiated with a 40Gy dose (þIR)
compared to untreated controls (-IR). (E) Relative levels of p21 and
Mdm2 mRNA in HCT116 cells transfected with either VO or PBF for
24 h and then irradiatedwith a 20Gy dose (þIR) or untreated (-IR) prior
to harvesting after 8 h. (F) Relative levels of PBF and p21 mRNA in
HCT116 cells transfected with either PBF-specific or control siRNA for
48 h and then irradiatedwith a 20Gy dose (þIR) or untreated (-IR) prior
to harvesting after 8 h. Data presented as mean SE. *, P< 0.05; **,
P< 0.01; ***, P< 0.001. NS - not significant.
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PBF Expression Correlates with Genetic Instability and
Invasiveness
Dysregulation of p53 function has been linked to GI
and invasiveness of colorectal tumorigenesis. We
therefore examined whether PBF expression also
correlated with levels of GI in colorectal tumors.
Those tumors with greater than two-fold induction of
PBF mRNA compared to their matched normals had
significantly higher GI than those tumors with lower
than two-fold induction (Figure 6A; P<0.05), indi-
cating an association between PBF expression and GI
in colorectal tumors.
We observed that PBF expression was also signifi-
cantly higher (2-fold; P<0.05) in WT TP53
colorectal tumors with evidence of Extramural
Vascular Invasion (EMVI) (Figure 6B), an indepen-
dent predictor of recurrence and poorer overall
survival [37,38], than those that failed to invade. In
keeping with this, subsequent in vitro experiments
demonstrated 60% greater migration of PBF-trans-
fected HCT116 cells at 24 h (Figure 6C; P<0.001)
compared to VO-transfected controls, which further
suggests a role for PBF in promoting cell movement
in colorectal tumorigenesis.
Taken together these results demonstrate the ability
of PBF to bind and regulate p53 activity, as well
as correlating with clinical parameters of colorectal
cancer. We therefore propose that PBF has a role in
colorectal tumorigenesis through inhibition of p53
activity, which may involve the induction of cancer
cell migration and invasion.
DISCUSSION
PBF is a relatively well-described protein
[21,23,24,26,39–41] comprising 180 amino acids
which is ubiquitously expressed [18], but shares no
significant homology with other human proteins. It is
highly conserved across animal species, suggesting
both unique function and significant evolutionary
importance. We previously reported overexpression of
PBF in thyroid [21] and breast cancers [23], and
demonstrated it to be a transforming gene in vitro
Figure 5. PBF correlates with mutational status and expression of
p53 in colorectal tumors. (A) Schematic of the protein domain
structure of p53 showing the relative position of p53 mutations
identified in human colorectal tumors. (right) A representative
electropherogram trace of the somatic TP53 mutation (c.856G>A)
in colorectal tumor from patient #13. (B) Western blot analysis of p53
expression in matched normal [N] and cancer [C] colorectal pairs
(n¼ 15). Cancers marked with an asterisk contain a somatic TP53
mutation or deletion. Six mutations (M1-M6 as indicated) were used to
generate p53 mutant expression constructs as described in (E). (C)
Relative p53 protein levels in WT TP53 colorectal tumors with either
low (n¼ 3) or high (n¼ 4; > 2-fold induction) PBF expression.
Magnified image of representative colorectal tumor with either low
(#14) or high (#7) PBF expression alongwith p53 and b-actin levels. (D)
Relative PBF expression in colorectal tumors with either WT or mutant
TP53. All protein levels were normalized to b-actin. Data presented as
mean SE. *, P< 0.05. (E) Co-IP assays in H1299 cells showing
interaction between PBF and p53 mutants. Lysates from cells
transfected with PBF and WT p53 (WT) or the indicated p53 mutant
(M1-M6) were immunoprecipated with an anti-PBF antibody. Purified
proteinswere analysed byWestern blotting using an anti-p53 antibody
and are shown relative to control cells transfected with PBF alone (  ).
(below) Analysis of total protein lysate demonstrating the presence of
p53, PBF and b-actin as loading control.
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and tumorigenic in vivo [21]. However, the precise role
of PBF in tumorigenesis is unknown. Our current study
provides the first evidence that PBF should be consid-
ered a new aetiological factor in colorectal cancer, as
well as a potential prognostic biomarker.
Here, we characterized PBF in human colorectal
tumors in order to gain possible insights into the role
of PBF in tumorigenesis. Strikingly, PBF was overex-
pressed in the majority of colorectal tumors examined
at both the mRNA (2.5-fold) and protein (6-fold)
level, which was comparable to that seen in papillary
thyroid tumors [21]. Previous studies have indicated
that the expression of PBF appears to be greater in
more aggressive cancers [21,42]. High PBF expression,
for instance, was significantly correlated with locore-
gional recurrence and distant metastases in 153
patients with papillary thyroid cancer [42]. We also
observed an 8-fold increase in PBF mRNA in recurrent
papillary thyroid cancer compared to 2.7-fold in
tumors without recurrence [21]. Similarly in this
study, PBF was most abundant in colorectal tumors
with reported EMVI, raised GI and somatic TP53
mutations, all features linked with recurrence and
poorer patient survival [13,37,38,43]. Together these
findings indicate that PBF represents a promising
prognostic indicator for aggressive colorectal tumors.
The mechanisms governing colorectal tumorigene-
sis are yet to be fully defined, despite recent progress
in identifying new roles for p53 in tumor progres-
sion [6,8,9,11]. The control of p53 activity itself is
known to be highly complex involving a myriad of
different pathways, and interactions with both posi-
tive and negative regulatory factors [5,44]. Our data
clearly show that PBF interacts specifically with p53 as
Figure 6. Increased genetic instability and invasiveness of cells with
elevated PBF. (A) Relative GI indexes of colorectal tumors with either
low (n¼ 12) or high PBF mRNA levels (n¼ 6; > 2-fold induction). (B)
Relative PBF expression in WT TP53 human colorectal tumors either
without (  ) or with (þ) EMVI. Protein levels were normalized to b-
actin. Representative Western blot of PBF expression in colorectal
tumors either without (patient #8) or with EMVI (patient #4), along
with b-actin, is also shown. (C) Relative proportion of migrating
HCT116 cells transfected with either VO or PBF after 24 h (n¼ 8).
Representative images are shown of transfected cells taken with an
inverted light microscope (upper panels) and then digitally processed
(middle panels) for data analysis using ImageJ software. Magnified
regions are shown in lower panels. Circles (dashed) of identical
diameter are superimposed on images of both VO and PBF-transfected
cells to highlight greater migration of PBF-transfected cells.
*, P< 0.05; ***, P< 0.001.
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evidenced by GST pull-down, coimmunoprecipita-
tion and oligonucleotide pull-down assays. The
relative level of p53:PBF coimmunoprecipitates in
colorectal cells was enhanced by gamma-irradiation,
which likely reflects the greater abundance of stabi-
lized protein as p53 protein levels were, as expected,
raised in irradiated HCT116 cells, in contrast to
negligible changes in PBF protein. Interestingly,
pull-down assays using deletion mutants of PBF
showed that p53 did not bind to the C-terminal
region (residues 149–180), which is known to bind
PTTG1 [18]. Instead, a largely undefined region in PBF
from residues 94 to 149 was implicated as deleting this
region abolished the PBF: p53 interaction. In future
studies we plan to map the precise interaction
between PBF and p53 by further extensive mutational
analysis. In particular, it will be important to
investigate whether a short stretch of acidic amino
acids located between residues 133–149 in PBF can
mimic similar sequences identified in the E3 ligase
Mdm2 that have been described to promote interac-
tion with p53 [45,46].
In addition to interfering with binding of p53 to a
consensus DNA site, we also demonstrated that PBF
has a role in diminishing p53 stability as PBF over-
expression significantly increased p53 turnover in
colorectal cells. Further evidence was provided by
increased ubiquitination of p53 in PBF-transfected
cells as shown by the accumulation of high mwt p53
conjugates. Our results are therefore consistent with
other proteins such as Mdm2 that can influence p53
activity in multiple ways. For example, it is known
that interactions between the acidic domain of Mdm2
at the DNA-binding core of p53 are involved in
ubiquitination and degradation of p53 [45,47], as well
as for inhibiting DNA-binding [48]. It is unlikely
however that PBF is functioning as an E3 ligase such as
Mdm2 to promote p53 ubiquitination as it does not
contain a well-defined domain with either ubiquitin-
conjugating (UBC) [49] or E3 ligase [50] activity.
Instead, we envisage that PBF may have a role in
promoting the interaction of p53 with proteins
known to alter its ubiquitination or acetylation status,
such as Mdm2 [51], HDAC1 [52], PCAF [53] or
Tip50 [54]. Importantly, we were also able to show
that binding of PBF to p53 had functional conse-
quences, with reduced transactivation in p53 reporter
assays and increased survival of irradiated HCT116
cells, as well as altered mRNA expression for p53-
regulated genes in both PBF-transfected and PBF-
depleted cells.
In colorectal cancer overexpression of PTTG1 has
been well-described in invasive disease [14], with
particular significance as a marker for patient surviv-
al [15]. A role for PBF in regulating PTTG1 activity was
indicated in one study where nuclear translocation of
PTTG1 was enhanced by PBF in COS-7 cells [18]. We
therefore expected that PBF might facilitate the role of
PTTG1 as a human securin in colorectal tumorigene-
sis to inhibit mitosis and generate intrachromosomal
breaks, as well as increasing the interaction between
PTTG1 and p53 [16,55]. Our current data, however,
suggest that the interaction of PBF with p53 might
represent a new pathway in colorectal tumorigenesis
that is independent of PTTG1 action. In particular, we
found that a mutant of PBF (M1) lacking the entire
PTTG1-binding domain (PTTG1 BD), as identified by
Chien and colleagues [18], was still capable of binding
p53 and abrogating function in a transactivation p53
reporter assay, as well as efficiently transforming NIH-
3T3 cells in soft agar assays. In addition, preliminary
co-IP experiments showed that the PBF:p53 interac-
tion was not significantly altered in PTTG1-depleted
cells (data not shown). These findings are therefore
supportive of an independence of action for PBF.
A high frequency of TP53 mutations have been
identified in colorectal tumors [35]. Our data are in
keeping with those in the literature with about 50% of
tumors demonstrating either a somatic or deletion
mutation in TP53, with two of the amino acids
identified, that is, R273 and R282, known to be
“hotspot” residues [12]. Importantly, we were able to
show significant associations between PBF with the
mutational status and expression of p53 in colorectal
tumors. Of particular significance was that WT TP53
tumors with high PBF expression had reduced p53
levels compared to those with low PBF expression,
which further emphasizes a putative interaction
between these two genes in vivo. However, greater
PBF expression was also evident in colorectal tumors
with somatic TP53 mutations, a scenario in which
patients have a shorter survival time than those with a
WT TP53 gene [13]. We are now planning to expand
this study and investigate the wider clinical associa-
tions of these findings in a larger cohort of colorectal
tumors.
It will also be important to determine the precise
biological consequences of the interaction between
PBF and mutant p53. Our coimmunoprecipitation
experiments in p53-null H1299 cells showed a strong
interaction between PBF and six different p53
mutants. It is unclear why elevated levels of PBF
present in colorectal tumors were unable to bind and
degrade stabilized mutant p53. It has been proposed
however that Mdm2-mediated turnover of mutant
p53 is ineffective in tumors due to binding of heat-
shock proteins [56–58] and the inability of p53
mutant protein to transactivate Mdm2 [59]. Recently,
we showed that the action of PBF on p53 in thyroid
cells appeared to be Mdm2-dependent as the inhibitor
nutlin-3, which blocks binding of Mdm2 to p53,
abrogated the ability of PBF to diminish p53 stabili-
ty [51]. Based on these observations our current model
is that elevated PBF levels in colorectal tumors are
unable to promote destabilization of mutant p53
due to diminished regulation by the E3 ligase Mdm2.
We are also currently investigating whether PBF
might represent a novel mutant p53-interacting
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partner such as Sp1 [36] that can enhance the
oncogenic activity of mutant p53.
Cancer cell migration and invasion are important
initial steps in tumor metastasis. Of relevance in this
study was the observation that PBF expression was
higher in colorectal tumors with reported EMVI, a
poor prognostic feature linked with recurrence and
poorer overall survival, in which malignant cells have
invaded endothelial cell-lined blood vessels [37,38].
Previously, we have shown that high PBF expression
was associated with cancer cell invasion in breast
MCF-7 cells [23]. Similarly in this study, we demon-
strated that PBF overexpression induced the migra-
tion of colorectal HCT116 cells. The mechanism
for the ability of PBF to promote cell movement
still needs to be clarified. However, it was recently
suggested that p53 controls a specific gene signature
to suppress intestinal tumor progression, and
that loss of p53 in the intestinal epithelium of
Csnk1a1Dgutp53Dgut mice was responsible for rapid
invasiveness [6]. Therefore, based on these observa-
tions and other recent studies on p53 [7–11], we
propose that the ability of PBF to bind and regulate
p53 function might have a direct role in promoting
colorectal cancer cell migration and invasion.
In summary, we present evidence for PBF as a novel
interacting partner of p53, which modulates p53
transactivation capabilities by disrupting promoter
binding and altering p53 stability. This is the first
study to demonstrate overexpression of PBF in
colorectal cancer, particularly in invasive WT p53
and mutant p53 tumors, thus implying that this gene
should be investigated in future studies as a novel
aetiological marker in colorectal tumorigenesis. We
recently showed that thyroid-related inhibitory prop-
erties of PBF can be abrogated with the Src inhibitor
PP1 to promote radioiodine uptake [41]. Thus, the
ability of PBF activity to be regulated by inhibitors
suggests that targeting PBF might also represent a
promising therapeutic strategy in colorectal cancer.
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